vs
BXP, Inc.（BXP）与GENMAB A/S（GMAB）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是BXP, Inc.的1.1倍（$925.0M vs $872.1M），GENMAB A/S净利率更高（36.3% vs 15.3%，领先21.1%），GENMAB A/S同比增速更快（18.7% vs 0.8%）
BXP是美国头部商业地产投资信托企业，核心业务为持有、运营及开发A级高端写字楼资产，项目覆盖纽约、波士顿、旧金山等美国核心都市圈，服务企业、科技、专业服务等领域的多元租户。
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
BXP vs GMAB — 直观对比
营收规模更大
GMAB
是对方的1.1倍
$872.1M
营收增速更快
GMAB
高出17.9%
0.8%
净利率更高
GMAB
高出21.1%
15.3%
损益表 — Q1 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $872.1M | $925.0M |
| 净利润 | $133.0M | $336.0M |
| 毛利率 | — | 93.8% |
| 营业利润率 | — | 38.9% |
| 净利率 | 15.3% | 36.3% |
| 营收同比 | 0.8% | 18.7% |
| 净利润同比 | 53.0% | 65.5% |
| 每股收益（稀释后） | $1.69 | $5.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BXPGMAB
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | — | ||
| Q3 25 | $871.5M | — | ||
| Q2 25 | $868.5M | $925.0M | ||
| Q1 25 | $865.2M | — | ||
| Q4 24 | $858.6M | — | ||
| Q3 24 | $859.2M | — | ||
| Q2 24 | $850.5M | $779.0M |
净利润BXPGMAB
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | — | ||
| Q3 25 | $-121.7M | — | ||
| Q2 25 | $89.0M | $336.0M | ||
| Q1 25 | $61.2M | — | ||
| Q4 24 | $-228.9M | — | ||
| Q3 24 | $83.6M | — | ||
| Q2 24 | $79.6M | $203.0M |
毛利率BXPGMAB
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | — | ||
| Q3 25 | 59.3% | — | ||
| Q2 25 | 59.2% | 93.8% | ||
| Q1 25 | 59.2% | — | ||
| Q4 24 | 59.7% | — | ||
| Q3 24 | 59.5% | — | ||
| Q2 24 | 59.8% | 96.4% |
营业利润率BXPGMAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 38.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 30.3% |
净利率BXPGMAB
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | — | ||
| Q3 25 | -14.0% | — | ||
| Q2 25 | 10.2% | 36.3% | ||
| Q1 25 | 7.1% | — | ||
| Q4 24 | -26.7% | — | ||
| Q3 24 | 9.7% | — | ||
| Q2 24 | 9.4% | 26.1% |
每股收益（稀释后）BXPGMAB
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | — | ||
| Q3 25 | $-0.77 | — | ||
| Q2 25 | $0.56 | $5.42 | ||
| Q1 25 | $0.39 | — | ||
| Q4 24 | $-1.46 | — | ||
| Q3 24 | $0.53 | — | ||
| Q2 24 | $0.51 | $3.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $512.8M | $1.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.7B | $5.3B |
| 总资产 | $25.1B | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BXPGMAB
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $861.1M | — | ||
| Q2 25 | $447.0M | $1.3B | ||
| Q1 25 | $398.1M | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $685.4M | $622.0M |
股东权益BXPGMAB
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.3B | $5.3B | ||
| Q1 25 | $5.3B | — | ||
| Q4 24 | $5.4B | — | ||
| Q3 24 | $5.8B | — | ||
| Q2 24 | $5.8B | $4.4B |
总资产BXPGMAB
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | — | ||
| Q3 25 | $26.0B | — | ||
| Q2 25 | $25.6B | $6.5B | ||
| Q1 25 | $25.4B | — | ||
| Q4 24 | $26.1B | — | ||
| Q3 24 | $26.4B | — | ||
| Q2 24 | $25.5B | $5.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $349.0M |
| 自由现金流经营现金流 - 资本支出 | — | $327.0M |
| 自由现金流率自由现金流/营收 | — | 35.4% |
| 资本支出强度资本支出/营收 | 1.5% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 1.04× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BXPGMAB
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | — | ||
| Q3 25 | $274.2M | — | ||
| Q2 25 | $353.1M | $349.0M | ||
| Q1 25 | $210.0M | — | ||
| Q4 24 | $383.7M | — | ||
| Q3 24 | $286.1M | — | ||
| Q2 24 | $367.1M | $438.0M |
自由现金流BXPGMAB
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | — | ||
| Q3 25 | $231.6M | — | ||
| Q2 25 | $281.5M | $327.0M | ||
| Q1 25 | $152.6M | — | ||
| Q4 24 | $312.5M | — | ||
| Q3 24 | $234.5M | — | ||
| Q2 24 | $332.4M | $430.0M |
自由现金流率BXPGMAB
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | — | ||
| Q3 25 | 26.6% | — | ||
| Q2 25 | 32.4% | 35.4% | ||
| Q1 25 | 17.6% | — | ||
| Q4 24 | 36.4% | — | ||
| Q3 24 | 27.3% | — | ||
| Q2 24 | 39.1% | 55.2% |
资本支出强度BXPGMAB
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | — | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | 8.2% | 2.4% | ||
| Q1 25 | 6.6% | — | ||
| Q4 24 | 8.3% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 4.1% | 1.0% |
现金转化率BXPGMAB
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.97× | 1.04× | ||
| Q1 25 | 3.43× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.42× | — | ||
| Q2 24 | 4.61× | 2.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
